Evaluation of Predictors of Ineffectiveness of Antiviral Therapy for Chronic Hepatitis C in the Republic of Kazakhstan

Author:

Maikenova Arailym1,Nersesov Alexander1,Kuantay Elmira1,Kulimbet Mukhtar1,Yerlanova Yerkezhan1,Colombo Massimo Giuseppe2,Pavlov Chavdar3,Jumabayeva Almagul1,Nugmanova Balzhan1,Ayupova Venera4,Yarunina Raissa1,Kaulybekova Assel1,Alimkhan Ulzhalgas1,Churukova Nazugum1,Kaltayev Ilyas1,Alpysbayeva Gulnar5,Atasheva Roza6,Balabek Aliya4,Kassymova Tatyana7,Kurmangazin Meirambek8,Kyzdarbekov Askar9,Mukanova Gulnara10,Nurpeisova Aiman11,Sapargaliyeva Nazigul12,Shamsivaliyeva Kunsulu13,Zhumatayeva Saule14,Ligay Yuliya15

Affiliation:

1. Kazakh National Medical University

2. Hepatology Translational Research Center in Humanita

3. I.M. Sechenov First Moscow State Medical University

4. Hepatology Center in Almaty

5. Kyzylorda City central clinic

6. Mangistau Regional Multidisciplinary Hospital

7. Shymkent Regional Clinical Hospital

8. West Kazakhstan Marat Ospanov State Medical University

9. Hepatology Center in Zhambyl Region

10. West Kazakhstan Regional Clinical Hospital

11. Hepatology Center in Kostanay Region

12. East Kazakhstan Regional Hospital

13. Hepatology Center in Astana

14. Kokshetau Multidisciplinary City Hospital

15. Atyrau Regional Hospital No. 2

Abstract

Abstract This study aims to identify the predictors of ineffectiveness in antiviral therapy for chronic hepatitis C (CHC) in Kazakhstan. The rising prevalence and mortality rates associated with CHC globally and within Kazakhstan underscore the need for effective antiviral treatment strategies. Despite the introduction of direct-acting antiviral agents (DAAs) with high cure rates, a subset of patients fails to achieve a sustained virological response (SVR). We conducted a multicenter retrospective matched case-control study across 13 regions of Kazakhstan, including 812 patients with CHC. The study involved patients registered in healthcare organizations who had received DAAs, focusing on those who did not reach SVR. Variables such as demographic characteristics, virological status, stage of liver disease, comorbidities, lifestyle factors, therapy regimen, and patient adherence were analyzed. Logistic regression analysis identified multiple factors associated with increased risk of non-response to therapy, including comorbid conditions like arterial hypertension, hepatocellular carcinoma, and lifestyle factors. The study highlights the complexity of CHC treatment in Kazakhstan, emphasizing the need for personalized treatment plans and addressing comorbid conditions and lifestyle factors. This research contributes to understanding the multifaceted nature of CHC treatment response and aids in optimizing therapeutic strategies in similar healthcare settings.

Publisher

Research Square Platform LLC

Reference29 articles.

1. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review;Alberts CJ;Lancet Gastroenterol Hepatol,2022

2. Jumabayeva, A. et al. Prevalence of Viral Hepatitis B, C, and D in Kazakhstan. Scientific World Journal 2022, (2022).

3. Hepatitis C;World Health Organization;Hepatitis C,2023

4. Epidemiological Characteristics of Chronic Viral Hepatitis in Kazakhstan: Data from Unified Nationwide Electronic Healthcare System 2014–2019;Ashimkhanova A;Infect Drug Resist,2022

5. ИССЛЕДОВАНИЙ 2015–2017 ГОДОВ ПО КЛИНИКОЭПИДЕМИОЛОГИЧЕСКОЙ ХАРАКТЕРИСТИКЕ БОЛЕЗНЕЙ ПЕЧЕНИ В КАЗАХСТАНЕ;Нерсесов AB;Medicine,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3